drugset / Trial / NCT00884234

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00884234 ↗

Phase 2 Completed 30 enrolled Revance Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of 2 sequential doses of RT001 compared to vehicle control following applications at Baseline (Day 0) and Week 2.

Timeline

Start
2009-02
Primary completion
2009-04
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject RT001 Protein / enzyme biologic — Topical

Indications